Key TakeawaysLLY has declined 10.6% this month after disappointing third-quarter results.The drug maker has seen strong ...

Conditions are getting a bit more challenging for the drugmaker.

Hunter Associates Investment Management LLC trimmed its position in Eli Lilly and Company (NYSE:LLY – Free Report) by 0.8% in ...

Lilly (NYSE: LLY) makes drugs including Mounjaro for type 2 diabetes and Zepbound for obesity. For 2023, it reported $34 ...

Aristotle Atlantic Partners, LLC, an investment advisor ... Aristotle Large Cap Growth Strategy highlighted stocks like Eli ...

PLEASANT PRAIRIE, Wis. — Eli Lilly and Company has acquired a state-of-the-art injectable medicine manufacturing facility ...

Mount Yale Investment Advisors LLC lowered its stake in Eli Lilly and Company (NYSE:LLY – Free Report) by 4.5% during the ...

Lifecore now operates at less than 35% utilization, meaning that it can almost triple revenue with virtually no additional ...

The FDA became aware of the problem after a patient submitted a complaint to the regulator that a vial of semaglutide from ...

SAN ANTONIO — Oral semaglutide 25 mg appears to be just as effective in promoting weight loss and other beneficial outcomes ...

For Q3 2024, Aristotle Atlantic’s Large Cap Growth Composite posted a total return of 1.26% gross of fees, underperforming ...

DePauw’s annual career fair, hosted by the Hubbard Center, successful took place on Wednesday, Sept. 25, from 11 a.m. to 1:30 ...